press

Press06/06/2019

EMN AT EHA SYMPOSIUM: BRINGING TOGETHER SCIENTIFIC COMMUNITY AND PHARMACEUTICAL INDUSTRY

In Amsterdam (June 13th 2019), a symposium chaired by Prof. Mario Boccadoro, Hematologist at the University of Turin, member of the European Myeloma Network and President of the Executive Committee of the EMN Research Italy Working Group, will deal with a very topical issue: the relationship between the scientific community and pharmaceutical companies – a highly relevant topic in the era of personalized medicine.

Prof. Mario Boccadoro, Hematologist at the University of Turin, President of the Executive Committee of the EMN Research Italy Working Group and member of the EMN European Myeloma Network, the leading network in the research and treatment in the myeloma field, will chair the Symposium "The value of collaborative research in hematology: bringing industry and scientific groups closer towards a common goal". The symposium will take place on Thursday 13th June 2019 at the RAI Exhibition and Convention Center in Amsterdam as part of the 24th annual EHA (European Hematology Association) conference scheduled from June 13th to 16th. The satellite symposium is promoted by HeaDS (Health Data Specialists), a Contract Research Organization (CRO), specialized in conducting clinical studies in the field of oncological hematology, and aims to analyse the complex relationship between scientific research and the pharmaceutical industry seeking new and more efficient collaborations and identifying areas for improvement.

A topical subject, for the first time dealt with an articulated approach and under different aspects. In fact, Tobias Kampfenkel of Janssen Pharmaceutical, Meletios A. Dimopoulos, member of the European Myeloma Network, Meral Beksac of the Balkan Myeloma Group and Ioannis Orfanidis, Health Data Specialists, will take part in the satellite symposium chaired by Prof. Boccadoro. In the current scenario, where personalized approaches and tailored therapies are needed to achieve high response rates to treatments, we need extremely precise and reliable data and appropriate clinical studies to analyse different drug combinations.

It is clear that a close and efficient collaboration between the scientific community and the pharmaceutical industry is fundamental and as such must be managed and regulated in all its aspects to allow significant and solid progress in the treatment of multiple myeloma and other plasma cell dyscrasias.

COOKIES DISCLAIMER

This website uses cookies to improve your browsing experience. By continuing to browse this website, you agree to our use of cookies. Read the privacy policy